The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1372
September 5, 2011
View Complete Issue         Table of Contents 2019 
Ticagrelor (Brilinta) - Better than Clopidogrel (Plavix)?
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.
Ticagrelor (Brilinta) - Better than Clopidogrel (Plavix)?
September 5, 2011 (Issue: 1372)
The FDA has approved ticagrelor (Brilinta – AstraZeneca), an oral antiplatelet drug, for use with low-dose aspirin to reduce the rate of thrombotic cardiovascular events in patients with acute coronary syndrome (ACS). It will compete with...more
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App
  • FREE online per issue CME/CE
Purchase this article:
Title: Ticagrelor (Brilinta) - Better than Clopidogrel (Plavix)?
Article code: 1372a
 Electronic, downloadable article - $45


Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.